Radiolabeled Monoclonal Antibody Therapy After Radiation Therapy in Treating Patients With Primary Brain Tumors

Part of paid clinical trials in Durham, North Carolina.

Sponsor
Darell D. Bigner, MD, PhD
Study ID
NCT00003484
Phase
PHASE1
Status
Completed

Conditions

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

  • carmustine — DRUG
  • irinotecan hydrochloride — DRUG
  • surgical procedure — PROCEDURE
  • iodine I 131 monoclonal antibody 81C6 — RADIATION

Study Details

RATIONALE: Monoclonal antibodies can locate tumor cells and deliver tumor-killing substances, such as radioactive iodine, to them without harming normal cells. PURPOSE: Phase I trial to study the effectiveness of radiolabeled monoclonal antibody after radiation therapy in treating patients with newly diagnosed primary brain tumors that can be surgically resected.

Key Dates

Start date
Sep 30, 1997
Status verified
Apr 2015
Primary completion
Nov 30, 2003
Completion
Mar 31, 2010

Study Design

Enrollment
21 participants (actual)
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT

Locations (1)

FacilityCityStateZIPSite coordinators
Duke Comprehensive Cancer CenterDurhamNorth Carolina27710-

Find similar trials in Durham, NC

By condition
Neuroblastoma
By specialty
OncologyPediatric oncology
By research site
Duke Comprehensive Cancer Center· Durham, NC

Related Studies